April 4, 2024
Journal Article
Proteomic Determinants of variation in Cholesterol Efflux: Observations From the Dallas Heart Study
Abstract
High-density lipoproteins (HDL) are promising targets for predicting and treating atherosclerotic cardiovascular disease (ASCVD) as they mediate removal of excess cholesterol from lipid-laden macrophages that accumulate in the vasculature. This functional property of HDL, termed cholesterol efflux capacity (CEC), is inversely associated with ASCVD. HDLs are compositionally diverse associating with >250 different proteins, but their relative contribution to CEC remains poorly understood. Our goal was to identify and define key HDL-associated proteins that modulate CEC in humans. The proteomic signature of plasma HDL was quantified in 36 individuals in the multi-ethnic population-based DHS (Dallas Heart Study) cohort that exhibited persistent extreme high (>=90th%) or low CEC (Published: April 4, 2024